- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- FDA advisory committee recommends approval for Bristol-Myers Squibb's, AstraZeneca's metreleptin in generalized lipodystrophy
- Bristol-Myers Squibb sells off diabetes business
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- FDA approves Mekinist in combination with Tafinlar to treat patients with advanced melanoma
SHANGHAI — Drug maker Bristol-Myers Squibb is opening a new testing facility in China under collaboration with a local company there, Bristol said Monday.
WuXi PharmaTech will build, equip and operate the 25,000-sq.-ft. lab in Shanghai to store and test stability samples and perform other services for Bristol.
“This new agreement expands our already productive relationship with Bristol-Myers Squibb, a valued customer for many years,” WuXi CEO and chairman Ge Li said. “We will continue to help them to improve their [research and development] productivity with our innovation-driven, cost-effective and fully integrated R&D service platform.”